Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...
Drug
Huapont Life Sciences Gains NMPA Approval for Generic Daivobet
China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval...
Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received breakthrough therapy designation (BTD)...
Hengrui’s HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received breakthrough therapy...
Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
Sanofi (EPA: SAN, NASDAQ: SNY) announced that it has received approval from Japan’s Ministry of...
Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
EMA’s CHMP Issues Negative Opinion on Lilly’s Kisunla for Alzheimer’s
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
BMS’s Opdivo/Yervoy Combo Approved by NMPA for First-Line HCC Treatment
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received approval from China’s National Medical...
Roche’s Ocrevus Approved by China’s NMPA for Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that it has received marketing approval...
AstraZeneca’s Imfinzi Approved by FDA for Bladder Cancer Treatment
The US Food and Drug Administration (FDA) has approved AstraZeneca’s (NASDAQ: AZN) PD-L1 inhibitor Imfinzi...
Sanofi’s Qfitlia Approved by FDA for Hemophilia A and B Prophylaxis
France-based Sanofi (EPA: SAN, NASDAQ: SNY) has announced receiving marketing approval from the US Food...
Brii Biosciences Presents Elebsiran Phase II Data at APASL 2025 Meeting
China-based Brii Biosciences Ltd (HKG: 2137) has published the latest data from its ongoing Phase...
IASO Biotherapeutics’ Fucaso Approved in Macao for Relapsed Multiple Myeloma
China-based IASO Biotherapeutics announced that the New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Eli Lilly Launches Kisunla in China for Early Alzheimer’s Treatment
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has officially launched Kisunla (donanemab) in...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma
Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...
Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention
Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...
Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...
TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies
Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...